Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 3/20 | 0.54 |
| ▸ | PPARD | Q03181 | 3/20 | 0.54 |
| ▸ | PPARA | Q07869 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.53 |
| ▸ | CYSLTR2 | Q9NS75 | 8/20 | 0.52 |
| ▸ | CYSLTR1 | Q9Y271 | 8/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6938386 | 0.96 | GRM2 (0.58) | PPARGPPARDPPARALMNACYP1A2 | |
| SCHEMBL6936012 | 0.91 | CYSLTR2 (0.54) | PPARGPPARDPPARALMNACYP1A2 | |
| SCHEMBL6938042 | 0.90 | CYSLTR2 (0.53) | PPARGPPARDPPARALMNACYP1A2 | |
| SCHEMBL8892285 | 0.90 | PPARG (0.45) | PPARGPPARDPPARALMNACYP1A2 | |
| SCHEMBL4343526 | 0.88 | PPARG (0.67) | PPARGPPARDPPARALMNACYP1A2 | |
| SCHEMBL6933735 | 0.86 | PPARG (0.52) | PPARGPPARDPPARALMNACYP1A2 | |
| SCHEMBL9042867 | 0.86 | PPARG (0.56) | PPARGPPARDPPARALMNACYP1A2 | |
| SCHEMBL6362913 | 0.84 | GRM2 (0.72) | PPARGPPARDPPARALMNACYP1A2 | |
| SCHEMBL10693092 | 0.84 | CYSLTR2 (0.71) | PPARGPPARDPPARALMNACYP1A2 | |
| SCHEMBL10690507 | 0.84 | CYSLTR2 (0.69) | PPARGPPARDPPARALMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0888278-B1 | ANTIDIABETIC AGENTS | MERCK & CO INC (US) | 2003-07-23 | — | — | EP | disclosed |
| EP-0888278-A4 | ANTIDIABETIC AGENTS | MERCK & CO INC (US) | 1999-06-30 | — | — | EP | disclosed |
| EP-0888278-A1 | ANTIDIABETIC AGENTS | Merck & Co., Inc. (US) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997049690-A1 | A METHOD FOR TREATING MENIERE'S DISEASE | MERCK & CO., INC. (US) | 1997-12-31 | — | — | WO | disclosed |
| WO-1997028149-A1 | METHOD FOR RAISING HDL CHOLESTEROL LEVELS | MERCK & CO., INC. (US) | 1997-08-07 | — | — | WO | disclosed |
| WO-1997028115-A1 | ANTIDIABETIC AGENTS | MERCK & CO., INC. (US) | 1997-08-07 | — | — | WO | disclosed |